Antibody to the hepatitis delta virus (anti-δ) was detected in 112 out of 2487 (5%) individuals fortuitously found to have the hepatitis B surface antigen (HBsAg) in the blood. Liver function was impaired in 38% (43 of 112) of the anti-δ-positive carriers but in only 9% (215 of 2375) of the anti-δ-negative subjects (p<0·001). Liver biopsy specimens were obtained from 31 antibody-positive and 97 antibody-negative subjects with impaired liver function. Important histological changes were observed in 61% of the 31 antibody-positive carriers (7 chronic active hepatitis, 4 active cirrhosis, 8 inactive cirrhosis) but in only 19% of the 97 antibody-negative carriers (p<0·001). The presence of anti-δ in serum identifies a subpopulation of apparently healthy HBsAg carriers whose risk of underlying liver disease is four times higher than that in the ordinary carrier. The identification of anti-δ in a symptom-free HBsAg carrier with abnormal liver function is thus an indication for a diagnostic liver biopsy.

Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers / S. ARICO', M. RIZZETTO, A.R. ZANETTI, S. DIANA, M. ARNONE, A. ASCIONE, G. PASTORE, M. ARAGONA, F. CAREDDA, G. MARINUCCI, P. FARCI, N. CAPORASO, A. DENTICO, G. RAIMONDO, A. CRAXI. - In: THE LANCET. - ISSN 0140-6736. - 326:ii(1985), pp. 356-358. [10.1016/S0140-6736(85)92497-3]

Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers

A.R. ZANETTI;
1985

Abstract

Antibody to the hepatitis delta virus (anti-δ) was detected in 112 out of 2487 (5%) individuals fortuitously found to have the hepatitis B surface antigen (HBsAg) in the blood. Liver function was impaired in 38% (43 of 112) of the anti-δ-positive carriers but in only 9% (215 of 2375) of the anti-δ-negative subjects (p<0·001). Liver biopsy specimens were obtained from 31 antibody-positive and 97 antibody-negative subjects with impaired liver function. Important histological changes were observed in 61% of the 31 antibody-positive carriers (7 chronic active hepatitis, 4 active cirrhosis, 8 inactive cirrhosis) but in only 19% of the 97 antibody-negative carriers (p<0·001). The presence of anti-δ in serum identifies a subpopulation of apparently healthy HBsAg carriers whose risk of underlying liver disease is four times higher than that in the ordinary carrier. The identification of anti-δ in a symptom-free HBsAg carrier with abnormal liver function is thus an indication for a diagnostic liver biopsy.
Settore MED/42 - Igiene Generale e Applicata
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/187892
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 53
  • ???jsp.display-item.citation.isi??? ND
social impact